Research ArticleClinical Studies

Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel

MASAKI SHIOTA, MOTONOBU NAKAMURA, AKIRA YOKOMIZO, TOSHIHISA TOMODA, NAOTAKA SAKAMOTO, NARIHITO SEKI, SHUJI HASEGAWA, TAKAKAZU YUNOKI, MASAHIKO HARANO, KENTARO KUROIWA and MASATOSHI ETO
Anticancer Research January 2020, 40 (1) 335-339; DOI: https://doi.org/10.21873/anticanres.13957

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Clinical outcomes of cabazitaxel chemotherapy in patients with or without prior use of ARAT agents. (A-C) Best PSA response (A), progression-free survival (B), and overall survival (C) in patients with metastatic CRPC treated with cabazitaxel chemotherapy according to prior use of ARAT agents.

Tables

  • Table I.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel
MASAKI SHIOTA, MOTONOBU NAKAMURA, AKIRA YOKOMIZO, TOSHIHISA TOMODA, NAOTAKA SAKAMOTO, NARIHITO SEKI, SHUJI HASEGAWA, TAKAKAZU YUNOKI, MASAHIKO HARANO, KENTARO KUROIWA, MASATOSHI ETO
Anticancer Research Jan 2020, 40 (1) 335-339; DOI: 10.21873/anticanres.13957
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords